Related Experiment Videos
Clinical experience with apomorphine hydrochloride: the first 107 patients
R Martínez1, A Puigvert, J M Pomerol
1Department of Andrology, Fundación Puigvert, Barcelona, Spain.
The Journal of Urology
|November 25, 2003
Summary
Apomorphine hydrochloride effectively treats erectile dysfunction, with a global response rate of 26.1%. This central-acting drug demonstrates high tolerability and a low incidence of adverse effects, making it a viable treatment option.
Area of Science:
- Pharmacology
- Urology
- Andrology
Background:
- Erectile dysfunction (ED) is a common condition affecting men's sexual health.
- Central-acting agents offer a novel therapeutic approach for ED management.
Purpose of the Study:
- To evaluate the efficacy and safety of apomorphine hydrochloride in patients with erectile dysfunction.
- To determine the optimal dosage and response rates for apomorphine hydrochloride in ED treatment.
Main Methods:
- A randomized assessment of 107 male patients diagnosed with erectile dysfunction.
- Apomorphine hydrochloride was administered at initial doses of 2 mg and 3 mg.
- Efficacy was defined as achieving sufficient erection for satisfactory intercourse.
Main Results:
- The global response rate to apomorphine hydrochloride was 26.1%.
- Response rates were 23.5% for 2 mg and 28.5% for 3 mg doses.
- Adverse effects were reported in 8.4% of patients, primarily nausea.
Conclusions:
- Apomorphine hydrochloride is the first centrally acting drug for inducing erections.
- The drug exhibits high tolerability and a low adverse event profile.
- Minimal drug interactions are expected, facilitating its use in patients with comorbidities.